Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “neutral” rating restated by equities researchers at JPMorgan Chase & Co. in a research note issued on Wednesday. They currently have a $65.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $55.00. JPMorgan Chase & Co.’s price target points to a potential downside of 14.28% from the company’s previous close.
Several other equities research analysts also recently commented on ESPR. Northland Securities restated a “buy” rating and issued a $72.00 target price on shares of Esperion Therapeutics in a research note on Friday, November 10th. Chardan Capital restated a “neutral” rating and issued a $75.00 target price (up previously from $20.00) on shares of Esperion Therapeutics in a research note on Tuesday, December 5th. BidaskClub downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Needham & Company LLC upgraded shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and boosted their target price for the company from $72.00 to $81.00 in a research note on Thursday, December 14th. Finally, Bank of America upgraded shares of Esperion Therapeutics from a “neutral” rating to a “buy” rating and set a $76.00 target price on the stock in a research note on Friday, January 5th. Seven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $79.54.
Shares of Esperion Therapeutics (ESPR) traded up $0.04 during trading on Wednesday, reaching $75.83. 736,700 shares of the company’s stock traded hands, compared to its average volume of 593,602. The company has a market cap of $2,008.38, a price-to-earnings ratio of -10.96 and a beta of 2.64. Esperion Therapeutics has a 12-month low of $20.39 and a 12-month high of $82.18.
Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Tuesday, February 20th. The biopharmaceutical company reported ($1.44) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.80) by $0.36. During the same quarter last year, the company posted ($1.29) earnings per share. analysts expect that Esperion Therapeutics will post -6.39 earnings per share for the current fiscal year.
In related news, Director Nicole Vitullo sold 9,326 shares of the company’s stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $53.85, for a total transaction of $502,205.10. Following the transaction, the director now owns 2,472 shares in the company, valued at approximately $133,117.20. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 32.50% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Chartwell Investment Partners LLC acquired a new position in Esperion Therapeutics during the 3rd quarter worth about $1,374,000. Hamilton Lane Advisors LLC acquired a new position in Esperion Therapeutics during the 4th quarter valued at about $7,594,000. Macquarie Group Ltd. acquired a new position in Esperion Therapeutics during the 2nd quarter valued at about $1,182,000. OxFORD Asset Management LLP acquired a new position in Esperion Therapeutics during the 3rd quarter valued at about $715,000. Finally, Rothschild Asset Management Inc. acquired a new position in Esperion Therapeutics during the 3rd quarter valued at about $1,124,000. Institutional investors and hedge funds own 87.67% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/02/22/esperion-therapeutics-espr-price-target-increased-to-65-00-by-analysts-at-jpmorgan-chase-co.html.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.